Literature DB >> 1958447

Metoprolol oxidation polymorphism in a Korean population: comparison with native Japanese and Chinese populations.

D R Sohn1, S G Shin, C W Park, M Kusaka, K Chiba, T Ishizaki.   

Abstract

We examined metoprolol oxidation capacity in 218 unrelated, healthy Korean subjects using the 8 h urinary metabolic ratio (MR) of metoprolol to alpha-hydroxymetoprolol after an oral dose of 100 mg metoprolol tartrate. The results were compared with those from 295 Japanese and 107 mainland Chinese whose metoprolol oxidation capacities were assessed in a similar manner. The frequency of occurrence of poor metabolisers (PMs) was 0.5% (1/218) in the Korean, 0.7% (2/295) in the Japanese and 0% in the Chinese population. However, the respective mean (+/- s.d.) MRs (0.84 +/- 1.14 and 0.87 +/- 0.90) in the Korean and Japanese extensive metabolisers (EMs) were significantly (P less than 0.001) less than that in the Chinese EMs (2.81 +/- 2.35), and the mode of the distribution histogram and the probit plot of data for Chinese EMs were shifted to the right compared with those for Korean and Japanese EMs. The results indicate that Koreans, like Japanese and mainland Chinese, have a much lower frequency of the PM phenotype of debrisoquine/sparteine-type oxidation compared with that reported for Caucasian populations. Chinese EMs appear to have a lower capacity to metabolise metoprolol to alpha-hydroxymetoprolol compared with Korean or Japanese EMs.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1958447      PMCID: PMC1368614          DOI: 10.1111/j.1365-2125.1991.tb03939.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  13 in total

Review 1.  Interethnic variation of drug metabolism.

Authors:  W Kalow
Journal:  Trends Pharmacol Sci       Date:  1991-03       Impact factor: 14.819

Review 2.  The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects.

Authors:  M Eichelbaum; A S Gross
Journal:  Pharmacol Ther       Date:  1990       Impact factor: 12.310

3.  Disassociation between debrisoquine hydroxylation phenotype and genotype among Chinese.

Authors:  Q Y Yue; L Bertilsson; M L Dahl-Puustinen; J Säwe; F Sjöqvist; I Johansson; M Ingelman-Sundberg
Journal:  Lancet       Date:  1989-10-07       Impact factor: 79.321

Review 4.  Pharmacogenetics and its clinical implications. Part II. Oxidation polymorphism.

Authors:  Y Horai; T Ishizaki
Journal:  Ration Drug Ther       Date:  1988-06

5.  Simultaneous determination of metoprolol and alpha-hydroxymetoprolol in human plasma and urine by liquid chromatography with a preliminary observation on metoprolol oxidation in Japanese subjects.

Authors:  Y Horai; T Ishizaki; M Kusaka; G Tsujimoto; K Hashimoto
Journal:  Ther Drug Monit       Date:  1988       Impact factor: 3.681

6.  Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies.

Authors:  J C McGourty; J H Silas; M S Lennard; G T Tucker; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1985-12       Impact factor: 4.335

7.  A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin.

Authors:  E Steiner; L Iselius; G Alván; J Lindsten; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1985-10       Impact factor: 6.875

8.  Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese.

Authors:  Y Horai; M Nakano; T Ishizaki; K Ishikawa; H H Zhou; B I Zhou; C L Liao; L M Zhang
Journal:  Clin Pharmacol Ther       Date:  1989-08       Impact factor: 6.875

9.  Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs.

Authors:  R C Skoda; F J Gonzalez; A Demierre; U A Meyer
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

10.  N-acetylation polymorphism of dapsone in a Japanese population.

Authors:  Y Horai; T Ishizaki
Journal:  Br J Clin Pharmacol       Date:  1988-04       Impact factor: 4.335

View more
  17 in total

Review 1.  Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs.

Authors:  Leif Bertilsson; Marja-Liisa Dahl; Per Dalén; Ayman Al-Shurbaji
Journal:  Br J Clin Pharmacol       Date:  2002-02       Impact factor: 4.335

2.  Effect of the CYP2D6 genotype on the pharmacokinetics of tropisetron in healthy Korean subjects.

Authors:  Myo-Kyoung Kim; Joo-Youn Cho; Hyeong-Seok Lim; Kyoung-Seop Hong; Jae-Yong Chung; Kyun-Seop Bae; Dal-Seok Oh; Sang-Goo Shin; Sang-Hun Lee; Dong-Ho Lee; Bumchan Min; In-Jin Jang
Journal:  Eur J Clin Pharmacol       Date:  2003-05-01       Impact factor: 2.953

3.  Limited effects of frequent CYP2D6*36-*10 tandem duplication allele on in vivo dextromethorphan metabolism in a Japanese population.

Authors:  Kazuma Kiyotani; Makiko Shimizu; Toshio Kumai; Tetsuya Kamataki; Shinichi Kobayashi; Hiroshi Yamazaki
Journal:  Eur J Clin Pharmacol       Date:  2010-08-11       Impact factor: 2.953

4.  Inhibition of CYP2D6 by quinidine and its effects on the metabolism of cilostazol.

Authors:  S L Bramer; A Suri
Journal:  Clin Pharmacokinet       Date:  1999       Impact factor: 6.447

Review 5.  Opioid metabolism.

Authors:  Howard S Smith
Journal:  Mayo Clin Proc       Date:  2009-07       Impact factor: 7.616

Review 6.  Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese.

Authors:  T Yokoi; T Kamataki
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

Review 7.  Pharmacokinetics of haloperidol: an update.

Authors:  S Kudo; T Ishizaki
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

8.  Metoprolol alpha-hydroxylation is a poor probe for debrizoquine oxidation (CYP2D6) polymorphism in Jordanians.

Authors:  H F al-Hadidi; Y M Irshaid; N M Rawashdeh
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

9.  Dextromethorphan O-demethylation polymorphism in Jordanians.

Authors:  Y M Irshaid; H F al-Hadidi; N M Rawashdeh
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

10.  Debrisoquine and mephenytoin oxidation in Sinhalese: a population study.

Authors:  K Weerasuriya; R L Jayakody; C A Smith; C R Wolf; G T Tucker; M S Lennard
Journal:  Br J Clin Pharmacol       Date:  1994-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.